Skip to main content
NeuronFeed
Home Investors Rock Springs Capital

Rock Springs Capital

Active VC
Portfolio Active
2
Latest Genesis Molecular AI
Deal flow
$400M
2 rounds
Unicorns
0
≥ $1B valuation
Founded
—
Latest
Aug 2025
Treeline Biosciences

About Rock Springs Capital

Venture capital firm tracking 2 AI investments, with focus on Drug Discovery and US startups. Total tracked deal flow: $400M.

Investment activity

2023–2025
$200M
$200M
1
'23
1
'25

Sector focus

💊 Drug Discovery 2
🩺 AI Medical 1
🏥 AI Healthcare 1

Geographic focus

US 2

Portfolio

2

Genesis Molecular AI

Generative AI for small-molecule drug discovery

Treeline Biosciences

Computational and experimental drug discovery for hard-to-drug cancer targets

Co-investors

8

Andreessen Horowitz (Bio + Health)

1 shared

Exor

1 shared

Aisling Capital

1 shared

Fidelity Investments

1 shared

Casdin Capital

1 shared

Ajax Health

1 shared

KKR

1 shared

OrbiMed

1 shared

Recent rounds

2
Aug 21, 2025 Series A $200M Treeline Biosciences
Aug 29, 2023 Series B $200M Genesis Molecular AI